Dosage inner coating and use thereof

By using shellac coating technology, the vitamin C degradation and dosage form speckling caused by choline and vitamin C coexistence is solved, and the stability and aesthetics of the dosage form are improved.

CN118946346APending Publication Date: 2024-11-12BALCHEM CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380024059.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-11
Filing Date
2023-03-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

When choline coexists with vitamin C in dietary supplements, it is easy to cause the degradation of vitamin C and black spots on the dosage form surface, affecting the aesthetics and effectiveness of the product, and it is difficult for the prior art to effectively prevent such degradation.

Method used

Shellac is used as a coating preparation to coat the active ingredients in the multi-component dosage form, especially vitamin C and choline, to reduce the degradation rate of vitamin C and prevent spotting by reducing contact with moisture and metals.

Benefits of technology

It effectively prevents the degradation of vitamin C and spotting in the dosage form, maintains the stability and aesthetics of the product, and extends the service life of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946346A_ABST
    Figure CN118946346A_ABST
Patent Text Reader

Abstract

The present disclosure relates to coated formulations for multi-component dosage forms including vitamin C and / or choline. The coated formulation surrounds the vitamin C and / or the choline in a multi-component dosage form, which prevents the dosage form from spotting.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 318,946, filed on March 11, 2022, entitled “Inner Coating of Dosage Forms and Applications Thereof”; the entire contents of the U.S. Provisional Application are incorporated herein by reference. Technical Field

[0003] The present disclosure relates to coating formulations and methods of use and preparation thereof.Thus, the present disclosure relates to the fields of chemistry, pharmacy and dietary supplements. Background Art

[0004] Choline is an important nutrient found in many foods. Although choline is available in dietary supplements, it is rarely included in dosage forms such as multivitamins that contain vitamin C. This is often due to choline’s hygroscopic nature. When vitamin C degrades, it creates dark spots on the surface of the dosage form, making it unattractive to consumers. Additionally, this reduces the potency of the vitamin C in the dosage form, forcing manufacturers to either over-formulate the dosage form or risk a failed vitamin C label claim.

[0005] When choline is present in the dosage form, choline absorbs moisture from the air or other components in the dosage form, accelerating the degradation of vitamin C. In addition, the presence of metals and metal oxides in the dosage form accelerates the degradation of vitamin C. In addition, other agents in the dosage form (such as magnesium oxide, ferrous fumarate and dicalcium phosphate) can also accelerate spotting. This accelerates the spotting caused by vitamin C degradation.

[0006] What is needed is a dosage form including vitamin C and optionally choline that reduces the degradation rate of the vitamin C to prevent spotting. Summary of the invention

[0007] Provided herein is a coating formulation comprising shellac that, when coated on at least one active ingredient in a multi-component dosage form, prevents spotting in the dosage form. In some embodiments, the concentration of the at least one active ingredient is about 50.0 mass % to about 95.0 mass % relative to the total mass of the at least one active ingredient and the coating formulation.

[0008] In some embodiments, the at least one active ingredient includes vitamin C. In some aspects, the vitamin C is selected from the group consisting of ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, and any combination thereof. In some other aspects, the vitamin C is present in an amount of about 50% to about 95% by mass relative to the combined mass of the vitamin C and the coating formulation.

[0009] In some embodiments, the at least one active ingredient includes choline. In some embodiments, the choline is selected from the group consisting of: choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, α-glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, choline and DHA ester, choline and 3-methyl-2-hexenoic acid (MHA) ester, choline and medium chain triglyceride ester, choline and other esters of fatty acids, other salts of choline, or a combination thereof. In some other aspects, the choline is present in an amount of about 50 mass % to about 95 mass % relative to the combined mass of the choline and the coating formulation.

[0010] In some embodiments, the concentration of shellac is about 1% to about 50% by mass relative to the combined mass of the at least one active ingredient and the coating formulation. In an exemplary embodiment, the coating formulation further includes at least one of hydroxypropyl cellulose, silicon dioxide, starch, microcrystalline cellulose, ethyl cellulose, talc, and combinations thereof.

[0011] In some aspects, the coating formulation further includes a silicate. In some other aspects, the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose or a combination thereof. In certain embodiments, the silicate comprises silicon dioxide, and the silicon dioxide is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient. In still other embodiments, the silicon dioxide is at least one of colloidal silicon dioxide or fumed silicon dioxide.

[0012] In some aspects, the coating formulation comprises cellulose or a derivative thereof. In some other aspects, the cellulose or a derivative thereof comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hypromellose, carboxymethyl cellulose or a combination thereof.

[0013] In some aspects, the coating formulation further comprises hydroxypropyl cellulose. In some other aspects, the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0% to about 10% by mass relative to the combined mass of the coating formulation and the at least one active ingredient.

[0014] In some aspects, the coating formulation further comprises microcrystalline cellulose. In some additional aspects, the microcrystalline cellulose is present in the coating formulation in an amount of about 0% to about 25% by mass relative to the combined mass of the coating formulation and the first active ingredient and the second active ingredient.

[0015] In some aspects, the coating formulation further comprises ethyl cellulose. In some other aspects, the ethyl cellulose is present in the coating formulation in an amount of about 0% to about 10% by mass relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0016] In some aspects, the coating formulation further includes starch. In some other aspects, the starch includes corn starch, potato starch, rice starch, wheat starch, tapioca starch or a combination thereof. In some other aspects, the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0017] Further provided herein are multi-ingredient dosage forms, the dosage forms comprising at least one active ingredient and a coating formulation, the coating formulation comprising shellac, wherein the coating formulation coats the at least one active ingredient. In some embodiments, the shellac is present in an amount of about 1 mass % to about 50 mass % relative to the total mass of the at least one active ingredient and the coating formulation. In some other embodiments, the concentration of the at least one active ingredient is about 50.0 mass % to about 95.0 mass % relative to the combined mass of the at least one active ingredient and the coating formulation.

[0018] In some embodiments, the at least one active ingredient includes vitamin C. In some aspects, the vitamin C is selected from the group consisting of ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, and any combination thereof. In some other aspects, the vitamin C is present in the dosage form in an amount of about 1 mg to about 2000 mg.

[0019] In some embodiments, the at least one active ingredient includes choline. In some embodiments, the choline is selected from the group consisting of: choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, α-glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, choline and DHA esters, choline and 3-methyl-2-hexenoic acid (MHA) esters, choline and medium chain triglyceride esters, choline and other esters of fatty acids, other salts of choline, or combinations thereof. In some other aspects, the choline is present in the dosage form in an amount of about 1 mg to about 2000 mg.

[0020] In some exemplary embodiments, the coating formulation further comprises silicate, starch, cellulose or a derivative thereof, or a combination thereof.

[0021] In an exemplary embodiment, at least one active ingredient includes vitamin C and choline, and both vitamin C and choline are coated by the coating formulation. In another exemplary embodiment, the at least one active ingredient includes choline and the dosage form further includes vitamin C, and the vitamin C is not coated by the coating formulation. In yet another exemplary embodiment, the at least one active ingredient includes vitamin C and the dosage form further includes choline, wherein the choline is not coated by the coating formulation.

[0022] In some embodiments, the multi-component dosage form is a tablet, capsule, soft candy, beverage, stick, suspension, granulation, powder, lozenge, pastille, granule, pill, caplet. In some embodiments, the dosage form further comprises at least one of a vitamin, a mineral, a supplement, and an excipient.

[0023] In some embodiments, the multi-component dosage form, wherein the multi-component dosage form shows little to no spotting after storage at 25°C and 20% relative humidity for about 18 days, 30 days, or 60 days. In some embodiments, the multi-component dosage form, wherein the multi-component dosage form shows little to no spotting after storage at 25°C and 30% relative humidity for about 18 days, 30 days, or 60 days. In some embodiments, the multi-component dosage form, wherein the multi-component dosage form shows little to no spotting after storage at 45°C and 20% relative humidity for about 18 days, 30 days, or 60 days. In some embodiments, the multi-component dosage form, wherein the multi-component dosage form shows little to no spotting after storage at 45°C and 30% relative humidity for about 18 days, 30 days, or 60 days.

[0024] Further provided herein is a method for preventing spotting in a dosage form. The method comprises providing an active ingredient comprising at least one of vitamin C and choline; coating the active ingredient in a coating formulation comprising shellac; and including the active ingredient coated in the coating formulation in a dosage form. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Shown is the spotting of the tablets of Example 1 containing vitamin C but no choline under different storage conditions.

[0026] Figures 2A-2D Four different commercially available tablets stored under different conditions are shown.

[0027] Figure 3 Shown is the spotting of the tablets of Example 1 containing choline and vitamin C under different storage conditions for 18 days. The temperature ranged from 25°C to 85°C and the relative humidity ranged from 0% RH to 60% RH.

[0028] Figure 4 The tablets of Example 1 containing choline and vitamin C are shown to be spotted under refrigerated storage conditions (4° C.) at 0% RH, 30% RH and 60% RH for 18 days.

[0029] Figure 5A and 5B The mottled appearance of tablets of Example 1 containing various forms of choline and vitamin C under different storage conditions is shown.

[0030] Fig. 6A and 6B The mottled appearance of tablets of Example 1 containing various dosage forms, different forms of vitamin C and choline under different storage conditions is shown.

[0031] Figure 7 The spotting of the tablets of Example 1, comprising vitamin C, choline and a coating formulation of the present disclosure including talc, under different storage conditions is shown.

[0032] Figure 8 The progression of spotting of a tablet of Example 1 comprising vitamin C, choline and a coating formulation of the present disclosure including talc under different storage conditions is shown.

[0033] Fig. 9 The progression of spotting of tablets containing vitamin C, choline and a coating formulation of the present disclosure consisting of shellac is shown under different storage conditions.

[0034] Fig.10 The progression of spotting of tablets of Example 1 under different storage conditions is shown, wherein the tablets contain vitamin C, choline, and a coating formulation of the present disclosure consisting of shellac or no coating formulation.

[0035] Fig.11The progression of spotting of a tablet of Example 1 containing a coating formulation of the present disclosure coated on choline, vitamin C, or both, under different storage conditions is shown.

[0036] Figures 12A-12G Shown are colorimeter graphs of various tablets having various coating formulations of the present disclosure.

[0037] Fig.13 Shown are the tablets and ΔE values ​​for various tablets containing various coating formulations of the present disclosure.

[0038] Figures 14A-14B Shown are colorimeter graphs of various tablets that do not contain the coating formulations of the present disclosure. Fig. 14C Exemplary samples used in colorimeter experiments are shown. DETAILED DESCRIPTION

[0039] It should be understood that the present disclosure is not limited to the specific methods, compositions or materials specified herein, but extends to equivalents thereof that will be recognized by those of ordinary skill in the relevant art. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting.

[0040] Concentrations, amounts, and other numerical data may be expressed or presented in this article in a range format. It should be understood that such range formats are used only for convenience and brevity, and should be flexibly interpreted to include not only the values ​​explicitly listed as range limits, but also all individual values ​​or subranges encompassed within the range, as if each value and subrange were explicitly listed. As an illustration, a numerical range of "about 2 to about 50" should be interpreted to include not only the explicitly stated values ​​of 2 to 50, but also all individual values ​​and subranges within the indicated range. Thus, this numerical range includes individual values ​​(such as 2, 2.4, 3, 3.7, 4, 5.5, 10, 10.1, 14, 15, 15.98, 20, 20.13, 23, 25.06, 30, 35.1, 38.0, 40, 44, 44.6, 45, 48) and sub-ranges (such as 1 to 3, 2 to 4, 5 to 10, 5 to 20, 5 to 25, 5 to 30, 5 to 35, 5 to 40, 5 to 50, 2 to 10, 2 to 20, 2 to 30, 2 to 40, 2 to 50, etc.). The same principle applies to ranges that list only one value as a minimum or maximum value. In addition, such interpretation should be applied regardless of the breadth of the described range or feature.

[0041] As used herein, the term "about" is used to provide flexibility for numerical range endpoints by specifying that a given value can be "slightly above" or "slightly below" the endpoint. For example, the endpoint can be within 10%, 8%, 5%, 3%, 2% or 1% of the listed value. In addition, for convenience and brevity, the numerical range of "about 50 mg / mL to about 80 mg / mL" should also be understood to provide support for the range of "50 mg / mL to 80 mg / mL". The endpoint may also be based on the variability allowed by appropriate regulatory agencies (such as the U.S. Food and Drug Administration (FDA), the United States Pharmacopeia (USP), etc.). As used herein, "comprises, comprising", "containing" and "having" etc. can have the meanings given to them in U.S. patent law, and can mean "includes, including", etc., and are generally interpreted as open terms. The term "consisting of or consists of" is a closed term, and only includes components, structures, steps, etc. specifically listed in conjunction with such terms and components, structures, steps, etc. that comply with U.S. patent law. "Consisting essentially of or consists essentially of" have the meanings generally ascribed to them under U.S. patent law. In particular, such terms are generally closed terms, except that the inclusion of additional items, materials, components, steps, or elements that do not materially affect the basic and novel characteristics or functions of the items to which they are related is permitted. For example, trace elements that are present in a composition but do not affect the properties or characteristics of the composition are permitted if present under the expression "consisting essentially of" even if not explicitly listed in the list of items following such terms. In this specification, when open-ended terms such as "comprising" or "including" are used, it should be understood that direct support should also be provided for the language "consisting essentially of" and "consisting of", as if explicitly stated, and vice versa.

[0042] As used herein, the term "spotting" refers to the formation of dark spots on a dosage form containing vitamin C and optionally choline chloride.

[0043] As used herein, the term "choline" refers to N,N,N-trimethylethanolammonium cation and various quaternary ammonium salts, phospholipid-bound forms of the cation, esters of the cation with fatty acids or medium-chain triglycerides, and other molecules containing the cation. Therefore, the term "choline" can be used interchangeably with "choline salt", "phospholipid-bound form of choline", "esters of choline with fatty acids", etc. However, when the term "choline salt" is used, it specifically refers to the salt form of the N,N,N-trimethylethanolammonium cation; when the term "ester of choline with medium-chain triglycerides" is used, it specifically refers to the esterified form of the N,N,N-trimethylethanolammonium cation; and the like.

[0044] As used herein, the term "vitamin C" refers to vitamin C with the molecular formula C6H7O6 - Ascorbate ions, as well as the acid, salt and oxidized forms of ascorbate ions. Therefore, the term "vitamin C" can be used interchangeably with "ascorbic acid". When the amount or concentration of vitamin C is mentioned herein, they generally refer to the concentration or amount of ascorbate ions; for example, the phrase "vitamin C can be present in an amount of 1 mg" generally refers to the amount of ascorbate ions as 1 mg in this article.

[0045] As used herein, the term "shellac" refers to a resin secreted by female lac insects. The term encompasses raw shellac, liquid shellac, and shellac processed, modified, or purified by methods known to those skilled in the art, particularly by known methods for preparing medicinal shellac. In addition, the term encompasses derivatives or analogs of shellac.

[0046] Disclosed herein is a coating formulation that can be used to prevent spotting in a multi-component dosage form containing vitamin C and optionally choline chloride. The coating formulation includes shellac. Without being bound by theory, the coating formulation can reduce the degradation rate of vitamin C by protecting vitamin C from moisture and reducing contact with other ingredients (such as metals and metal oxides) in the multi-component dosage form. Additionally or alternatively, without being bound by theory, the coating formulation can prevent the absorption of excess moisture from the environment or other ingredients in the dosage form by choline chloride, which may accelerate the degradation of vitamin C. This can also have the benefits of reducing the formation of metal oxides and reducing the increase of interactions with metals in the multi-component dosage form. In addition, the coating formulation is resistant to rupture during compression, thereby enabling the coating formulation to be used in tablets and other dosage forms manufactured by compression.

[0047] I. Composition

[0048] A. Coating preparations

[0049] Disclosed herein is a coating formulation that can be used to prevent spotting in a dosage form containing at least one active ingredient. The coating formulation comprises shellac. In some embodiments, the coating formulation may consist of or consist essentially of shellac. The coating formulation surrounds the active ingredient. The coating formulation may completely surround the active ingredient or may substantially surround the active ingredient (i.e., 95% or more of the active ingredient). Preferably, the coating formulation does not coat the entire dosage form, but only coats the following active ingredients.

[0050] The particle size of the active ingredient through coating (i.e. coating formulation plus active ingredient) can be about 1 micron to about 2000 microns. In some aspects, the particle size of the active ingredient through coating can be about 1 micron to about 50 microns, about 50 microns to about 100 microns, about 100 microns to about 250 microns, about 250 microns to about 500 microns, about 500 microns to about 750 microns, about 750 microns to about 1000 microns, about 1000 microns to about 1250 microns, about 1250 microns to about 1500 microns, about 1500 microns to about 1750 microns, or about 1750 microns to about 2000 microns. In some additional aspects, the particle size of the coated active ingredient can be from about 1 micron to about 100 microns, from about 1 micron to about 250 microns, from about 1 micron to about 500 microns, from about 1 micron to about 750 microns, from about 1 micron to about 1000 microns, from about 1 micron to about 1250 microns, from about 1 micron to about 1500 microns, from about 1 micron to about 1750 microns, from about 50 microns to about 2000 microns, from about 100 microns to about 2000 microns, from about 250 microns to about 2000 microns, from about 500 microns to about 2000 microns, from about 750 microns to about 2000 microns, from about 1000 microns to about 2000 microns, from about 1250 microns to about 2000 microns, or from about 1500 microns to about 2000 microns. In still other embodiments, the particle size of the coated active ingredient can be about 1 micron, 50 microns, 100 microns, 200 microns, 300 microns, 400 microns, 500 microns, 600 microns, 700 microns, 800 microns, 900 microns, 1000 microns, 1100 microns, 1200 microns, 1300 microns, 1400 microns, 1500 microns, 1600 microns, 1700 microns, 1800 microns, 1900 microns, or about 2000 microns.

[0051] Coating formulations can exist with an amount of about 5 mass % to about 50 mass % relative to the combined mass of at least one active ingredient and coating formulations. In some aspects, coating formulations can exist with an amount of about 5 mass % to about 10 mass %, about 5 mass % to about 15 mass %, about 5 mass % to about 20 mass %, about 5 mass % to about 25 mass %, about 5 mass % to about 30 mass %, about 5 mass % to about 35 mass %, about 5 mass % to about 40 mass %, about 5 mass % to about 45 mass %, about 45 mass % to about 50 mass %, about 40 mass % to about 50 mass %, about 35 mass % to about 50 mass %, about 30 mass % to about 50 mass %, about 25 mass % to about 50 mass %, about 2 mass % to about 50 mass %, about 15 mass % to about 50 mass % or about 10 mass % to about 50 mass % relative to the combined mass of at least one active ingredient and coating formulations. In some additional aspects, the coating formulation can be present in an amount of about 5 mass%, 7.5 mass%, 10 mass%, 12.5 mass%, 15 mass%, 17.5 mass%, 20 mass%, 22.5 mass%, 25 mass%, 27.5 mass%, 30 mass%, 32.5 mass%, 35 mass%, 37.5 mass%, 40 mass%, 42.5 mass%, 45 mass%, 47.5 mass%, or about 50 mass% relative to the combined mass of the at least one active ingredient and the coating formulation.

[0052] Shellac can be present in the coating formulation in an amount of about 1% to about 50% by mass relative to the combined mass of the at least one active ingredient and the coating formulation. In some aspects, shellac can be present in an amount of about 1% to about 5% by mass, about 1% to about 10% by mass, about 1% to about 15% by mass, about 1% to about 20% by mass, about 1% to about 25% by mass, about 1% to about 30% by mass, about 1% to about 35% by mass, about 1% to about 40% by mass, about 1% to about 45% by mass, about 45% to about 50% by mass, about 40% to about 50% by mass, about 35% to about 4 ... The invention also provides an amount of about 50 mass %, about 30 mass % to about 50 mass %, about 25 mass % to about 50 mass %, about 2 mass % to about 50 mass %, about 15 mass % to about 50 mass %, about 10 mass % to about 50 mass %, about 5 mass % to about 50 mass %, about 5 mass % to about 40 mass %, about 5 mass % to about 30 mass %, about 5 mass % to about 20 mass %, about 10 mass % to about 40 mass %, about 10 mass % to about 30 mass %, or about 10 mass % to about 20 mass %. In some other aspects, shellac can be present in an amount of about 1 mass %, 2.5 mass %, 5 mass %, 7.5 mass %, 10 mass %, 12.5 mass %, 15 mass %, 17.5 mass %, 20 mass %, 22.5 mass %, 25 mass %, 27.5 mass %, 30 mass %, 32.5 mass %, 35 mass %, 37.5 mass %, 40 mass %, 42.5 mass %, 45 mass %, 47.5 mass %, or about 50 mass %. In some embodiments, shellac can be present in an amount of about 5 mass % to about 20 mass % relative to the combined mass of at least one active ingredient and the coating formulation.

[0053] The coating formulation can include silicate, such as silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, and other silicates known in the art or combinations thereof. Silicates serve as adsorbents, anti-caking agents, glidants, disintegrants, etc. Silicon dioxide can include colloidal silicon dioxide, gas phase (pyrolysis) silicon dioxide or other forms of silicon dioxide. Silicates can be present in the coating formulation in an amount of about 0% by mass to about 10% by mass relative to the combined mass of the coating formulation and at least one active ingredient. In some aspects, the silicate can be present in the coating formulation in an amount of about 0% to about 2%, 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 7%, 0% to about 8%, about 0% to about 9%, about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 0.5% to about 5%, or about 1% to about 3% by mass, relative to the combined mass of the coating formulation and the at least one active ingredient. In some other aspects, silicate can be present in the coating formulation in an amount of about 0 mass % to about 1 mass %, about 1 mass % to about 2 mass %, about 2 mass % to about 3 mass %, about 3 mass % to about 4 mass %, about 4 mass % to about 5 mass %, about 5 mass % to about 6 mass %, about 6 mass % to about 7 mass %, about 7 mass % to about 8 mass %, about 8 mass % to about 9 mass %, or about 9 mass % to about 10 mass %. In another aspect, silicate can be present in the coating formulation in an amount of about 0.5 mass %, 1 mass %, 1.5 mass %, 2 mass %, 2.5 mass %, 3 mass %, about 4 mass %, about 5 mass %, about 6 mass %, about 7 mass %, about 8 mass %, about 9 mass %, or about 10 mass % relative to the combined mass of the coating formulation and at least one active ingredient. In an exemplary embodiment, the silicate is present in the coating formulation in an amount of about 0.5 mass % to about 3 mass % relative to the combined mass of the coating formulation and the at least one active ingredient. In another exemplary embodiment, the silicate is colloidal silicon dioxide.

[0054] Coating formulations can include starch, such as corn starch, potato starch, rice starch, wheat starch, tapioca starch and other starches, or a combination thereof. Starch serves as a lubricant and low solubility coating. Starch can be present in coating formulations with an amount of about 0 mass % to about 25 mass % relative to the combined mass of coating formulations and at least one active ingredient. In some aspects, starch can be present in coating formulations with an amount of about 0 mass % to about 5 mass %, about 5 mass % to about 10 mass %, about 10 mass % to about 15 mass %, about 15 mass % to about 20 mass % or about 20 mass % to about 25 mass %. In some other aspects, starch can be present in coating formulations with an amount of about 0 mass % to about 10 mass %, about 0 mass % to about 15 mass %, about 0 mass % to about 20 mass %, about 5 mass % to about 25 mass %, about 10 mass % to about 25 mass %, about 15 mass % to about 25 mass % or about 5 mass % to about 20 mass %. In still other aspects, starch can be present in the coating formulation in an amount of about 0 mass %, 1 mass %, 2 mass %, 3 mass %, 4 mass %, 5 mass %, 6 mass %, 7 mass %, 8 mass %, 9 mass %, 10 mass %, 11 mass %, 12 mass %, 13 mass %, 14 mass %, 15 mass %, 16 mass %, 17 mass %, 18 mass %, 19 mass %, 20 mass %, 21 mass %, 22 mass %, 23 mass %, 24 mass % or about 25 mass % relative to the combined mass of coating formulation and at least one active ingredient. In an exemplary embodiment, starch is present in the coating formulation in an amount of about 9 mass % to about 16 mass % relative to the combined mass of coating formulation and at least one active ingredient.

[0055] The coating formulation can include cellulose or its derivatives, such as microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose (e.g., hydroxymethyl cellulose acetate succinate), carboxymethyl cellulose (e.g., sodium carboxymethyl cellulose), and combinations thereof. In some aspects, cellulose can be mixed with other ingredients (such as carrageenan, phosphates (e.g., calcium phosphate), gums (e.g., guar gum), mannitol, silicates, etc.).

[0056] In some embodiments, the coating formulation may include microcrystalline cellulose. Microcrystalline cellulose serves as an adsorbent, compression aid, diluent, binder and disintegrant for dosage forms described herein. Microcrystalline cellulose may be present in a coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of a coating formulation and at least one active ingredient. In some aspects, microcrystalline cellulose may be present in an amount of about 0 mass % to about 5 mass %, about 5 mass % to about 10 mass %, about 10 mass % to about 15 mass %, about 15 mass % to about 20 mass % or about 20 mass % to about 25 mass % relative to the combined mass of a coating formulation and at least one active ingredient. In some other aspects, microcrystalline cellulose may be present in a coating formulation in an amount of about 0 mass % to about 10 mass %, about 0 mass % to about 15 mass %, about 0 mass % to about 20 mass %, about 5 mass % to about 25 mass %, about 10 mass % to about 25 mass %, about 15 mass % to about 25 mass % or about 5 mass % to about 20 mass %. In still other aspects, microcrystalline cellulose can be present in an amount of about 0 mass %, 1 mass %, 2 mass %, 3 mass %, 4 mass %, 5 mass %, 6 mass %, 7 mass %, 8 mass %, 9 mass %, 10 mass %, 11 mass %, 12 mass %, 13 mass %, 14 mass %, 15 mass %, 16 mass %, 17 mass %, 18 mass %, 19 mass %, 20 mass %, 21 mass %, 22 mass %, 23 mass %, 24 mass %, or about 25 mass % relative to the combined mass of the coating formulation and at least one active ingredient. In an exemplary embodiment, microcrystalline cellulose is present in an amount of about 9 mass % to about 12 mass % relative to the combined mass of the coating formulation and at least one active ingredient.

[0057] In some embodiments, the coating formulation may include hydroxypropyl cellulose. Hydroxypropyl cellulose increases the flexibility of the coating. Hydroxypropyl cellulose may be present in the coating formulation in an amount of about 0% to about 10% by mass relative to the combined mass of the coating formulation and at least one active ingredient. In some aspects, hydroxypropyl cellulose can be present in the coating formulation in an amount of about 0% to about 2%, 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 7%, 0% to about 8%, about 0% to about 9%, about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 0.5% to about 5%, or about 1% to about 3% by mass, relative to the combined mass of the coating formulation and the at least one active ingredient. In some other aspects, hydroxypropyl cellulose can be present in the coating formulation with an amount of about 0 mass % to about 1 mass %, about 1 mass % to about 2 mass %, about 2 mass % to about 3 mass %, about 3 mass % to about 4 mass %, about 4 mass % to about 5 mass %, about 5 mass % to about 6 mass %, about 6 mass % to about 7 mass %, about 7 mass % to about 8 mass %, about 8 mass % to about 9 mass %, or about 9 mass % to about 10 mass %. In still other aspects, hydroxypropyl cellulose can be present in the coating formulation with an amount of about 0.5 mass %, 1 mass %, 1.5 mass %, 2 mass %, 2.5 mass %, 3 mass %, about 4 mass %, about 5 mass %, about 6 mass %, about 7 mass %, about 8 mass %, about 9 mass %, or about 10 mass % relative to the combined mass of coating formulation and at least one active ingredient. In an exemplary embodiment, hydroxypropyl cellulose is present in the coating formulation in an amount of about 0.25 mass % to about 1.5 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0058] In some embodiments, the coating formulation may include hydroxypropyl methylcellulose. Hydroxypropyl methylcellulose increases the flexibility of the coating. Hydroxypropyl methylcellulose may be present in the coating formulation in an amount of about 0% to about 10% by mass relative to the combined mass of the coating formulation and at least one active ingredient. In some aspects, hydroxypropyl methylcellulose can be present in the coating formulation in an amount of about 0% to about 2%, 0% to about 3%, about 0% to about 4%, about 0% to about 5%, about 0% to about 6%, about 0% to about 7%, 0% to about 8%, about 0% to about 9%, about 1% to about 10%, about 2% to about 10%, about 3% to about 10%, about 4% to about 10%, about 5% to about 10%, about 6% to about 10%, about 7% to about 10%, about 8% to about 10%, about 0.5% to about 5%, or about 1% to about 3% by mass, relative to the combined mass of the coating formulation and the at least one active ingredient. In some other aspects, hydroxypropyl methylcellulose can be present in the coating formulation with an amount of about 0 mass % to about 1 mass %, about 1 mass % to about 2 mass %, about 2 mass % to about 3 mass %, about 3 mass % to about 4 mass %, about 4 mass % to about 5 mass %, about 5 mass % to about 6 mass %, about 6 mass % to about 7 mass %, about 7 mass % to about 8 mass %, about 8 mass % to about 9 mass %, or about 9 mass % to about 10 mass %. In still other aspects, hydroxypropyl methylcellulose can be present in the coating formulation with an amount of about 0.5 mass %, 1 mass %, 1.5 mass %, 2 mass %, 2.5 mass %, 3 mass %, about 4 mass %, about 5 mass %, about 6 mass %, about 7 mass %, about 8 mass %, about 9 mass % or about 10 mass % relative to the combined mass of coating formulation and at least one active ingredient.

[0059] In some embodiments, the coating formulation can further include ethyl cellulose.Ethyl cellulose can be present in coating formulations with an amount of about 0 mass % to about 10 mass % relative to the combined mass of coating formulations and at least one active ingredient.In some aspects, ethyl cellulose can be present in coating formulations with an amount of about 0 mass % to about 2 mass %, 0 mass % to about 3 mass %, about 0 mass % to about 4 mass %, about 0 mass % to about 5 mass %, about 0 mass % to about 6 mass %, about 0 mass % to about 7 mass %, 0 mass % to about 8 mass %, about 0 mass % to about 9 mass %, about 1 mass % to about 10 mass %, about 2 mass % to about 10 mass %, about 3 mass % to about 10 mass %, about 4 mass % to about 10 mass %, about 5 mass % to about 10 mass %, about 6 mass % to about 10 mass %, about 7 mass % to about 10 mass %, about 8 mass % to about 10 mass %, about 0.5 mass % to about 5 mass % or about 1 mass % to about 3 mass % relative to the combined mass of coating formulations and at least one active ingredient. In some other aspects, ethylcellulose can be present in the coating formulation in an amount of about 0 mass % to about 1 mass %, about 1 mass % to about 2 mass %, about 2 mass % to about 3 mass %, about 3 mass % to about 4 mass %, about 4 mass % to about 5 mass %, about 5 mass % to about 6 mass %, about 6 mass % to about 7 mass %, about 7 mass % to about 8 mass %, about 8 mass % to about 9 mass %, or about 9 mass % to about 10 mass %. In still other aspects, ethylcellulose can be present in the coating formulation in an amount of about 0.5 mass %, 1 mass %, 1.5 mass %, 2 mass %, 2.5 mass %, 3 mass %, about 4 mass %, about 5 mass %, about 6 mass %, about 7 mass %, about 8 mass %, about 9 mass %, or about 10 mass % relative to the combined mass of the coating formulation and at least one active ingredient. In an exemplary embodiment, the ethylcellulose is present in the coating formulation in an amount of about 0.1% to about 1% by mass relative to the combined mass of the coating formulation and the at least one active ingredient.

[0060] The coating formulation can further include one or more excipients. One or more excipients can include sugar (e.g., lactose, dextrin, maltodextrin, glucose, sucrose, fructose, maltose, galactose, etc.), sugar alcohol (e.g., sorbitol, mannitol, xylitol, lactitol, isomalt, maltitol, erythritol, hydrogenated starch hydrolysate, etc.), other silicates (e.g., calcium silicate, magnesium silicate and other forms of silicon dioxide), other derivatives of starch, other derivatives of cellulose (e.g., cellulose acetate, cellulose phthalate, etc.), alginate, stearate or stearic acid, dye, coloring agent, flavoring agent, lubricant, adhesive, filler, glidant, diluent, adsorbent, disintegrating agent, film former, compression aid and other excipients well known to those skilled in the art.

[0061] B. Active ingredients

[0062] Coating formulations coat at least one active ingredient contained in a multi-component dosage form.

[0063] The at least one active ingredient may include vitamin C and choline. In some exemplary embodiments, at least one active ingredient may include only vitamin C, only choline, or both vitamin C and choline. In some other exemplary embodiments, the multi-component dosage form may contain both vitamin C and choline, but only one active ingredient is coated with a coating formulation of the present disclosure. In still other exemplary embodiments, the multi-component dosage form may contain both vitamin C and choline, both of which are coated with a coating formulation of the present disclosure, but the composition of the coating formulation for vitamin C is different from the composition of the coating formulation for choline. In still other exemplary embodiments, the multi-component dosage form may contain both vitamin C and choline, both of which are coated with a coating formulation of the same composition.

[0064] The at least one active ingredient may include a fat-soluble vitamin or a derivative thereof, such as vitamin A, vitamin D, vitamin E, vitamin K, and other fat-soluble vitamins known in the art, and derivatives thereof.

[0065] The at least one active ingredient may comprise a water-soluble vitamin or a derivative thereof, such as folic acid, thiamine, riboflavin, niacin, biotin, pantothenic acid, pyridoxine, cobalamin, and other water-soluble vitamins known in the art, and derivatives thereof.

[0066] At least one active agent may comprise a nutritionally relevant metal, such as sodium, potassium, calcium, magnesium, iron, copper, zinc, manganese, cobalt, chromium, and other nutritionally relevant metals known in the art, and salts, complexes, or chelates thereof.

[0067] At least one active ingredient can comprise a drug or pharmaceutical agent, such as an analgesic, anti-inflammatory, antiarrhythmic, anti-asthmatic, antibacterial, antiviral, anticoagulant, antidepressant, antidiabetic, antiepileptic, antifungal, antihypertensive, antimalarial, antimigraine, antimuscarinic, antineoplastic, immunosuppressant, antiprotozoal, antithyroid, anxiolytic, sedative, hypnotic, neuroleptic, beta-blocker, cardiac inotropic, corticosteroid, diuretic, anti-Parkinsonian agent, gastrointestinal agent, antihistamine, histamine receptor antagonist, lipid regulator, muscle relaxant, nitrates and other antianginal drugs, nutritional agents, opioid analgesics, or stimulants.

[0068] i. Vitamin C

[0069] At least one active ingredient can include vitamin C. The vitamin C can include ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, or any other form of vitamin C known in the art, or a combination thereof. In some embodiments, the vitamin C is ascorbic acid.

[0070] In some embodiments, vitamin C can be present in an amount of about 50% to about 95% by mass relative to the combined mass of vitamin C and the coating formulation. In some aspects, vitamin C can be present in an amount of about 50% to about 55% by mass, about 55% to about 60% by mass, about 60% to about 65% by mass, about 65% to about 70% by mass, about 70% to about 75% by mass, about 75% to about 80% by mass, about 80% to about 85% by mass, about 85% to about 90% by mass, or about 90% to about 95% by mass relative to the combined mass of vitamin C and the coating formulation. In some additional aspects, vitamin C can be present in an amount of about 50% to about 60% by mass, about 50% to about 65% by mass, about 50% to about 70% by mass, about 50% to about 75% by mass, about 50% to about 80% by mass, about 50% to about 85% by mass, about 50% to about 90% by mass, about 55% to about 95% by mass, about 60% to about 95% by mass, about 65% to about 95% by mass, about 70% to about 95% by mass, about 75% to about 95% by mass, about 80% to about 95% by mass, or about 85% to about 95% by mass, relative to the combined mass of vitamin C and the coating formulation. In still other aspects, vitamin C can be present in an amount of about 50 mass %, 55 mass %, 60 mass %, 65 mass %, 70 mass %, 75 mass %, 80 mass %, 85 mass %, 90 mass %, or about 95 mass % relative to the combined mass of vitamin C and the coating formulation. In some exemplary embodiments, vitamin C can be present in an amount of about 70 mass % to about 80 mass % relative to the combined mass of vitamin C and the coating formulation.

[0071] ii. Choline

[0072] In some embodiments, at least one active ingredient may include choline. Choline may include choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, α-glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, esters of choline and DHA, esters of choline and 3-methyl-2-hexenoic acid (MHA), esters of choline and medium chain triglycerides, other esters of choline and fatty acids, other salts of choline, or combinations thereof. In some embodiments, choline is choline bitartrate.

[0073] In some embodiments, choline can be present in an amount of about 50% by mass to about 95% by mass relative to the combined mass of the coating formulation and choline. In some aspects, choline can be present in an amount of about 50% by mass to about 55% by mass, about 55% by mass to about 60% by mass, about 60% by mass to about 65% by mass, about 65% by mass to about 70% by mass, about 70% by mass to about 75% by mass, about 75% by mass to about 80% by mass, about 80% by mass to about 85% by mass, about 85% by mass to about 90% by mass, or about 90% by mass to about 95% by mass relative to the combined mass of the coating formulation and choline. In some additional aspects, choline can be present in an amount of about 50% to about 60% by mass, about 50% to about 65% by mass, about 50% to about 70% by mass, about 50% to about 75% by mass, about 50% to about 80% by mass, about 50% to about 85% by mass, about 50% to about 90% by mass, about 55% to about 95% by mass, about 60% to about 95% by mass, about 65% to about 95% by mass, about 70% to about 95% by mass, about 75% to about 95% by mass, about 80% to about 95% by mass, or about 85% to about 95% by mass, relative to the combined mass of vitamin C and the coating formulation. In still other aspects, choline can be present in an amount of about 50 mass %, 55 mass %, 60 mass %, 65 mass %, 70 mass %, 75 mass %, 80 mass %, 85 mass %, 90 mass %, or about 95 mass % relative to the combined mass of vitamin C and the coating formulation. In some exemplary embodiments, choline can be present in an amount of about 75 mass % and about 85 mass % relative to the combined mass of choline and the coating formulation.

[0074] C. Dosage form

[0075] Further described herein are multi-component dosage forms comprising a coating formulation of the present disclosure and at least one active ingredient. The coating formulation of the present disclosure is used to coat the active ingredient described in Section IB above; however, the coating formulation preferably does not coat the entire dosage form. The multi-component dosage form comprises additional ingredients, including vitamins, minerals, nutrients, supplements, drugs, excipients, fillers, binders, lubricants, plasticizers, etc.

[0076] In some embodiments, the multi-component dosage form can be a tablet, capsule, soft candy, beverage, stick, suspension, granulation, powder, lozenge, pastille, granule, pill, caplet, or other dosage forms known in the art. In embodiments where the dosage form is a tablet, the coating formulation can resist rupture when the ingredients are compressed in the tablet.

[0077] The multi-component dosage form can be modified to have a desired release profile. In some embodiments, the dosage form can be immediate release, controlled release, extended release, modified release, or sustained release.

[0078] The multi-component dosage form comprises a coating formulation of the present disclosure (see section IA of the detailed description herein). The coating formulation comprises shellac. The coating formulation coats at least one active ingredient in the multi-component dosage form (see section IB of the detailed description herein).

[0079] At least one active ingredient can include vitamin C. The vitamin C can include ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, or any other form of vitamin C known in the art, or a combination thereof. In some embodiments, the vitamin C is ascorbic acid.

[0080] In some embodiments, vitamin C can be present in an amount of about 50% to about 95% by mass relative to the combined mass of vitamin C and the coating formulation. In some aspects, vitamin C can be present in an amount of about 50% to about 55% by mass, about 55% to about 60% by mass, about 60% to about 65% by mass, about 65% to about 70% by mass, about 70% to about 75% by mass, about 75% to about 80% by mass, about 80% to about 85% by mass, about 85% to about 90% by mass, or about 90% to about 95% by mass relative to the combined mass of vitamin C and the coating formulation. In some additional aspects, vitamin C can be present in an amount of about 50% to about 60% by mass, about 50% to about 65% by mass, about 50% to about 70% by mass, about 50% to about 75% by mass, about 50% to about 80% by mass, about 50% to about 85% by mass, about 50% to about 90% by mass, about 55% to about 95% by mass, about 60% to about 95% by mass, about 65% to about 95% by mass, about 70% to about 95% by mass, about 75% to about 95% by mass, about 80% to about 95% by mass, or about 85% to about 95% by mass, relative to the combined mass of vitamin C and the coating formulation. In still other aspects, vitamin C can be present in an amount of about 50 mass %, 55 mass %, 60 mass %, 65 mass %, 70 mass %, 75 mass %, 80 mass %, 85 mass %, 90 mass %, or about 95 mass % relative to the combined mass of vitamin C and the coating formulation. In some exemplary embodiments, vitamin C can be present in an amount of about 70 mass % to about 80 mass % relative to the combined mass of vitamin C and the coating formulation.

[0081] In some embodiments, vitamin C can be present in a multi-component dosage form in an amount of about 1 mg to about 2000 mg. In some aspects, vitamin C can be present in a multi-component dosage form in an amount of about 1 mg to about 250 mg, about 250 mg to about 500 mg, about 500 mg to about 750 mg, about 750 mg to about 1000 mg, about 1000 mg to about 1250 mg, about 1250 mg to about 1500 mg, about 1500 mg to about 1750 mg, about 1750 mg to about 2000 mg. In some additional aspects, vitamin C can be present in a multi-component dosage form in an amount from about 1 mg to about 500 mg, about 1 mg to about 750 mg, about 1 mg to about 1000 mg, about 1 mg to about 1250 mg, about 1 mg to about 1500 mg, about 1 mg to about 1750 mg, about 250 mg to about 2000 mg, about 500 mg to about 2000 mg, about 750 mg to about 2000 mg, about 1000 mg to about 2000 mg, about 1250 mg to about 2000 mg, about 1500 mg to about 2000 mg, about 250 mg to about 1750 mg, about 500 mg to about 1500 mg, or about 750 mg to about 1250 mg. In still further aspects, vitamin C can be present in the multi-component dosage form in an amount of about 1 mg, 10 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 1900 mg, or about 2000 mg.

[0082] The at least one active ingredient may include choline. Choline may include choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, alpha glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, choline and DHA esters, choline and 3-methyl-2-hexenoic acid (MHA) esters, choline and medium chain triglyceride esters, choline and other esters of fatty acids, other salts of choline, or any other forms of choline known in the art, or combinations thereof. In some exemplary embodiments, choline is choline bitartrate.

[0083] Choline can be present in an amount of about 50% by mass to about 95% by mass relative to the combined mass of coating formulation and choline. In some aspects, choline can be present in an amount of about 50% by mass to about 55% by mass, about 55% by mass to about 60% by mass, about 60% by mass to about 65% by mass, about 65% by mass to about 70% by mass, about 70% by mass to about 75% by mass, about 75% by mass to about 80% by mass, about 80% by mass to about 85% by mass, about 85% by mass to about 90% by mass, or about 90% by mass to about 95% by mass relative to the combined mass of coating formulation and choline. In some additional aspects, choline can be present in an amount of about 50% to about 60% by mass, about 50% to about 65% by mass, about 50% to about 70% by mass, about 50% to about 75% by mass, about 50% to about 80% by mass, about 50% to about 85% by mass, about 50% to about 90% by mass, about 55% to about 95% by mass, about 60% to about 95% by mass, about 65% to about 95% by mass, about 70% to about 95% by mass, about 75% to about 95% by mass, about 80% to about 95% by mass, or about 85% to about 95% by mass, relative to the combined mass of vitamin C and the coating formulation. In still other aspects, choline can be present in an amount of about 50 mass %, 55 mass %, 60 mass %, 65 mass %, 70 mass %, 75 mass %, 80 mass %, 85 mass %, 90 mass %, or about 95 mass % relative to the combined mass of vitamin C and the coating formulation. In some exemplary embodiments, choline can be present in an amount between about 75 mass % and about 85 mass % relative to the combined mass of choline and the coating formulation.

[0084] Choline can be present in the multi-component dosage form in an amount of about 1 mg to about 2000 mg. In some aspects, choline can be present in the multi-component dosage form in an amount of about 1 mg to about 250 mg, about 250 mg to about 500 mg, about 500 mg to about 750 mg, about 750 mg to about 1000 mg, about 1000 mg to about 1250 mg, about 1250 mg to about 1500 mg, about 1500 mg to about 1750 mg, about 1750 mg to about 2000 mg. In some additional aspects, choline can be present in the multiple component dosage form in an amount of about 1 mg to about 500 mg, about 1 mg to about 750 mg, about 1 mg to about 1000 mg, about 1 mg to about 1250 mg, about 1 mg to about 1500 mg, about 1 mg to about 1750 mg, about 250 mg to about 2000 mg, about 500 mg to about 2000 mg, about 750 mg to about 2000 mg, about 1000 mg to about 2000 mg, about 1250 mg to about 2000 mg, about 1500 mg to about 2000 mg, about 250 mg to about 1750 mg, about 500 mg to about 1500 mg, or about 750 mg to about 1250 mg. In still further aspects, choline can be present in the multiple component dosage form in an amount of about 1 mg, 10 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 1900 mg, or about 2000 mg.

[0085] The multi-component dosage form may additionally include vitamins other than vitamin C. In some embodiments, the vitamins may include one or more of vitamin A (i.e., retinoids or carotenes), vitamin D (i.e., calciferol), vitamin E (i.e., α-tocopherol), vitamin K (i.e., phylloquinone or menaquinone), vitamin B1 (i.e., thiamine), vitamin B2 (i.e., riboflavin), vitamin B3 (i.e., niacin), vitamin B5 (i.e., pantothenic acid), vitamin B6 (i.e., pyridoxine), vitamin B7 (i.e., biotin), vitamin B12 (i.e., cyanocobalamin), vitamin B9 (i.e., natural folic acid or artificial folic acid), or other vitamins known to those of ordinary skill in the art.

[0086] The multi-component dosage form may additionally comprise minerals. In some embodiments, the mineral may comprise calcium, chloride, chromium, copper, fluoride, iodine, iron, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, sodium, sulfur, zinc, or other minerals known to those of ordinary skill in the art, or a pharmaceutically acceptable salt thereof.

[0087] The multi-component dosage form can additionally include a supplement. In some embodiments, the supplement can include 5-hydroxytryptophan, antioxidants, amino acids, activated charcoal, ashwagandha, astaxanthin, astragalus, berberine, bromelain, chlorella, chlorophyll, chondroitin, coconut oil, cod liver oil, colloidal silver, conjugated linoleic acid, creatine, damiana, echinacea, emu oil, evening primrose oil, fenugreek gum, fiber, fish oil, gamma-aminobutyric acid, garlic, ginger, ginkgo, glucomannan, glucosamine, glutathione, gotu kola, glutathione ... kola), hyaluronic acid, inositol, krill oil, licorice, lutein, maca, melatonin, moringa, omega fatty acids, prebiotics, probiotics, quercetin, rhodiola, saw palmetto, serrapeptase, taurine, turmeric, valerian, whey protein, xylitol, or other supplements known to those of ordinary skill in the art.

[0088] The multi-component dosage form may additionally comprise excipients. Excipients may comprise binders, plasticizers, fillers, bulking agents, disintegrants, glidants, lubricants, diluents, flavoring agents, flavor enhancers, flavor masking agents, odor masking agents, anti-caking agents, preservatives, humectants, wetting agents and other excipients known to those skilled in the art.

[0089] Multi-component dosage forms may include one or more additional active ingredients that are not coated with a coating formulation described herein.

[0090] After storage for about 18 days at a temperature of 25° C. and a relative humidity of 20%, the dosage forms of the present disclosure may show little or no spotting. Methods for measuring spotting are described in Section II below. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 25° C. and a relative humidity of 20%, the dosage forms may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0091] After storage for about 18 days at a temperature of 45° C. and a relative humidity of 20%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 45° C. and a relative humidity of 20%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0092] After storage for about 18 days at a temperature of 25° C. and a relative humidity of 30%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 25° C. and a relative humidity of 30%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0093] After storage for about 18 days at a temperature of 45° C. and a relative humidity of 30%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 45° C. and a relative humidity of 30%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0094] The multi-component dosage form can be suitable for administration to a subject. The subject can be a human, such as an adult or a child.

[0095] II. Methods

[0096] A. Methods for preventing dosage form spotting

[0097] A method for preventing spotting in a dosage form containing vitamin C and / or choline is described herein. The method comprises providing at least one active ingredient comprising at least one of vitamin C and choline; coating the at least one active ingredient in a coating formulation comprising shellac; and including the at least one active ingredient coated in the coating formulation in a dosage form. The coating formulation can be any coating formulation of the present disclosure described in Section I.

[0098] The step of coating at least one active ingredient in a coating formulation comprising shellac can be accomplished by pan coating, fluid bed coating, spray blending, or other coating methods known in the art.

[0099] The amount of spotting in the dosage form can be determined visually or by colorimetry. A colorimeter can be used to measure the amount of spotting in the dosage form by comparing the dosage form with a reference dosage form of the same composition. The color change can be measured by determining the total color difference (ΔE) of the dosage form compared to the reference dosage form, or by other methods known in the art, wherein ΔE is 0, indicating no color change. In some aspects, the average ΔE in the dosage form can be about 2.5 or less, or more preferably about 1.0 or less. For example, ΔE can be about 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or less than 0.1. ΔE is less than 1.0 and is generally considered to be a visually imperceptible color change. As used herein, a dosage form with "almost no spotting" refers to a dosage form having a ΔE of 2.5 or less compared to a reference dosage form; a dosage form with "no spotting" refers to a dosage form having a ΔE of 1.0 or less compared to a reference dosage form.

[0100] After storage for about 18 days at a temperature of 25° C. and a relative humidity of 20%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 25° C. and a relative humidity of 20%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0101] After storage for about 18 days at a temperature of 45° C. and a relative humidity of 20%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 45° C. and a relative humidity of 20%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0102] After storage for about 18 days at a temperature of 25° C. and a relative humidity of 30%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 25° C. and a relative humidity of 30%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0103] After storage for about 18 days at a temperature of 45° C. and a relative humidity of 30%, the dosage form of the present disclosure may show little or no spotting. For example, after storage for about 18 days, 30 days, 60 days, 90 days, 120 days, 180 days, 250 days, or 300 days at a temperature of 45° C. and a relative humidity of 30%, the dosage form may show little or no spotting. The amount of spotting can be determined by colorimeter measurement as described herein.

[0104] B. Methods for preparing coated formulations and dosage forms

[0105] The coating formulation of the present disclosure can be prepared by methods known in the art. The coating formulation can be prepared by dissolving the shellac and other coating formulation ingredients described in Section I above in a suitable solvent (such as an alcohol solvent). In one embodiment, the solvent can be ethanol.

[0106] Next, the active ingredient can be provided in a particulate form (eg, granules). The active ingredient can include choline or vitamin C, or any other active ingredient provided in Part I.

[0107] The coating formulation can then be applied to the active ingredient using coating methods known in the art (e.g., pan coating, spraying, etc.). When the solvent dries, the coating formulation is applied to the active ingredient to form a coated composition. The coated composition can be sieved to adjust the average particle size of the coated composition.

[0108] Dosage forms can be manufactured by various methods known to those skilled in the art. Dosage forms can be tablets, capsules, soft candies, beverages, sticks, suspensions, granulation, powders, lozenges, pastilles, granules, pills, capsules or other solid dosage forms known to those skilled in the art. In an exemplary embodiment, the dosage form is a tablet. Methods known to those of ordinary skill in the art can be used to incorporate the coated composition into the dosage form. For example, the coated composition can be combined with other ingredients and compressed to form a tablet. It should be understood that some unit operations can be modified or excluded to prevent damage to the coating formulation. For example, grinding dosage forms can be excluded to prevent damage to the coating formulation.

[0109] C. Application Method

[0110] Further provided herein is a method of administering the dosage form described in Section I. The method may comprise administering the dosage form of the present disclosure to a subject orally, sublingually or orally. The subject may be a human, such as an adult or a child. In some aspects, the subject may have a nutritional deficiency or deficiency, such as a vitamin C deficiency, a choline deficiency, or both. Therefore, in some aspects, the method may be suitable for supplementing nutrition to the subject.

[0111] Exemplary Embodiments

[0112] Embodiment 1: A coating formulation comprising shellac, wherein the coating formulation is used to coat at least one active ingredient in a multi-ingredient dosage form.

[0113] Embodiment 2: The coating formulation according to embodiment 1, wherein the concentration of the at least one active ingredient is about 50.0 mass % to about 95.0 mass % relative to the total mass of the at least one active ingredient and the coating formulation.

[0114] Embodiment 3: The coating formulation according to Embodiment 1 or Embodiment 2, wherein the at least one active ingredient comprises vitamin C.

[0115] Embodiment 4: According to the coating formulation of embodiment 3, the vitamin C is selected from the group consisting of ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, and any combination thereof.

[0116] Embodiment 5: The coating formulation according to embodiment 3 or embodiment 4, wherein the vitamin C is present in an amount of about 50% to about 95% by mass relative to the combined mass of the vitamin C and the coating formulation.

[0117] Embodiment 6: The coating formulation according to any one of Embodiments 1 to 5, wherein the at least one active ingredient comprises choline.

[0118] Embodiment 7: The coating formulation according to claim 6, wherein the choline is selected from the group consisting of: choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, alpha-glycerophosphorylcholine, cytidine diphosphate choline, folic acid choline, esters of choline and DHA, esters of choline and 3-methyl-2-hexenoic acid (MHA), esters of choline and medium chain triglycerides, other esters of choline and fatty acids, other salts of choline, or combinations thereof.

[0119] Embodiment 8: The coating formulation according to embodiment 6 or embodiment 7, wherein the choline is present in an amount of about 50% to about 95% by mass relative to the combined mass of the choline and the coating formulation.

[0120] Embodiment 9: The coating formulation according to any one of Embodiments 1 to 8, wherein the shellac is present in an amount of about 1 mass % to about 50 mass % relative to the combined mass of the at least one active ingredient and the coating formulation.

[0121] Embodiment 10: The coating formulation according to any one of embodiments 1 to 9, wherein the coating formulation further comprises a silicate.

[0122] Embodiment 11: The coating formulation according to embodiment 10, wherein the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, or a combination thereof.

[0123] Embodiment 12: The coating formulation according to embodiment 10 or embodiment 11, wherein the silicate is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0124] Embodiment 13: The coating formulation according to embodiment 11, wherein the silicon dioxide comprises colloidal silicon dioxide or fumed silicon dioxide.

[0125] Embodiment 14: The coating formulation according to any one of Embodiments 1 to 13, wherein the coating formulation further comprises cellulose or a derivative thereof.

[0126] Embodiment 15: According to the coating formulation of embodiment 14, the cellulose or its derivative comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, or a combination thereof.

[0127] Embodiment 16: The coating formulation according to embodiment 14 or embodiment 15, wherein the cellulose or its derivative comprises hydroxypropyl cellulose.

[0128] Embodiment 17: The coating formulation according to Embodiment 16, wherein the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0129] Embodiment 18: The coating formulation according to embodiment 14 or embodiment 15, wherein the cellulose or its derivative comprises microcrystalline cellulose.

[0130] Embodiment 19: The coating formulation according to Embodiment 18, wherein the microcrystalline cellulose is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient and the second active ingredient.

[0131] Embodiment 20: The coating formulation according to embodiment 14 or embodiment 15, wherein the cellulose or its derivative comprises ethyl cellulose.

[0132] Embodiment 21: The coating formulation according to Embodiment 20, wherein the ethylcellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0133] Embodiment 22: The coating formulation according to any one of Embodiments 1 to 21, wherein the coating formulation further comprises starch.

[0134] Embodiment 23: The coating formulation of embodiment 22, wherein the starch comprises corn starch, potato starch, rice starch, wheat starch, tapioca starch, or a combination thereof.

[0135] Embodiment 24: The coating formulation according to embodiment 22 or embodiment 23, wherein the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0136] Embodiment 25: A multi-ingredient dosage form, comprising: at least one active ingredient; and a coating formulation comprising shellac, wherein the coating formulation coats the at least one active ingredient.

[0137] Embodiment 26: The dosage form of Embodiment 25, wherein the at least one active ingredient comprises vitamin C.

[0138] Embodiment 27: The dosage form of Embodiment 26, wherein the vitamin C is present in the dosage form in an amount of about 1 mg to about 2000 mg.

[0139] Embodiment 28: The dosage form of embodiment 26 or embodiment 27, wherein the vitamin C is selected from the group consisting of ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, and any combination thereof.

[0140] Embodiment 29: The dosage form according to any one of Embodiments 25 to 28, wherein the at least one active ingredient comprises choline.

[0141] Embodiment 30: The dosage form of Embodiment 29, wherein the choline is present in the dosage form in an amount of about 1 mg to about 2000 mg.

[0142] Embodiment 31: A dosage form according to embodiment 29 or embodiment 30, wherein the choline is selected from the group consisting of: choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, alpha glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, esters of choline and DHA, esters of choline and 3-methyl-2-hexenoic acid (MHA), esters of choline and medium chain triglycerides, other esters of choline and fatty acids, other salts of choline, or combinations thereof.

[0143] Embodiment 32: The dosage form according to any one of Embodiments 25 to 31, wherein the shellac is present in an amount of about 1 mass % to about 50 mass % relative to the total mass of the at least one active ingredient and the coating formulation.

[0144] Embodiment 33: The dosage form according to any one of Embodiments 25 to 32, wherein the at least one active ingredient is present in an amount of about 50.0 mass % to about 95.0 mass % relative to the combined mass of the at least one active ingredient and the coating formulation.

[0145] Embodiment 34: The dosage form of any one of Embodiments 25 to 33, wherein the at least one active ingredient comprises vitamin C and choline, and wherein the choline is not coated by the coating formulation.

[0146] Embodiment 35: The dosage form of any one of Embodiments 25 to 33, wherein the at least one active ingredient comprises choline, and the dosage form further comprises vitamin C, wherein the vitamin C is not coated by the coating formulation.

[0147] Embodiment 36: The dosage form of any one of Embodiments 25 to 33, wherein the at least one active ingredient comprises vitamin C, and the dosage form further comprises choline, wherein the choline is not coated by the coating formulation.

[0148] Embodiment 37: The dosage form according to any one of embodiments 25 to 36, wherein the dosage form is a tablet, capsule, gummies, beverages, sticks, suspensions, granulations, powders, lozenges, pastilles, granules, pills, caplets.

[0149] Embodiment 38: The dosage form of any one of Embodiments 25 to 37, wherein the dosage form further comprises at least one of vitamins, minerals, supplements, and excipients.

[0150] Embodiment 39: The dosage form according to any one of Embodiments 25 to 38, wherein the dosage form further comprises an additional active ingredient that is not coated by the coating formulation.

[0151] Embodiment 40: The dosage form of any one of Embodiments 25 to 39, wherein the coating formulation further comprises a silicate.

[0152] Embodiment 41: The dosage form of embodiment 40, wherein the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, or a combination thereof.

[0153] Embodiment 42: The dosage form of embodiment 40 or embodiment 41, wherein the silicate is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0154] Embodiment 43: The dosage form of Embodiment 41, wherein the silicon dioxide comprises colloidal silicon dioxide or fumed silicon dioxide.

[0155] Embodiment 44: The dosage form according to any one of embodiments 25 to 43, wherein the coating formulation further comprises cellulose or a derivative thereof.

[0156] Embodiment 45: A dosage form according to embodiment 44, wherein the cellulose or its derivative comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, or a combination thereof.

[0157] Embodiment 46: The dosage form of Embodiment 44 or Embodiment 45, wherein the cellulose or derivative thereof comprises hydroxypropyl cellulose.

[0158] Embodiment 47: The dosage form of Embodiment 46, wherein the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0159] Embodiment 48: The dosage form of Embodiment 44 or Embodiment 45, wherein the cellulose or derivative thereof comprises microcrystalline cellulose.

[0160] Embodiment 49: The dosage form of embodiment 48, wherein the microcrystalline cellulose is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first and second active ingredients.

[0161] Embodiment 50: The dosage form of Embodiment 44 or Embodiment 45, wherein the cellulose or its derivative comprises ethyl cellulose.

[0162] Embodiment 51: The dosage form of Embodiment 50, wherein the ethylcellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0163] Embodiment 52: The dosage form of any one of Embodiments 25 to 51, wherein the coating formulation further comprises starch.

[0164] Embodiment 53: The dosage form of embodiment 52, wherein the starch comprises corn starch, potato starch, rice starch, wheat starch, tapioca starch, or a combination thereof.

[0165] Embodiment 54: The dosage form of embodiment 52 or embodiment 53, wherein the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0166] Embodiment 55: The dosage form of any one of Embodiments 25 to 54, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 18 days.

[0167] Embodiment 56: The dosage form of any one of embodiments 25 to 55, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 60 days.

[0168] Embodiment 57: The dosage form of any one of Embodiments 25 to 56, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 120 days.

[0169] Embodiment 58: The dosage form of any one of embodiments 25 to 57, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 18 days.

[0170] Embodiment 59: The dosage form of any one of embodiments 25 to 58, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 60 days.

[0171] Embodiment 60: The dosage form according to any one of embodiments 25 to 59, wherein the multi-component dosage form has little spotting after storage at 45°C and 20% relative humidity for about 120 days.

[0172] Embodiment 61: The dosage form of any one of Embodiments 25 to 60, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 18 days.

[0173] Embodiment 62: The dosage form of any one of embodiments 25 to 61, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 60 days.

[0174] Embodiment 63: The dosage form of any one of Embodiments 25 to 62, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 120 days.

[0175] Embodiment 64: The dosage form of any one of Embodiments 25 to 63, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 18 days.

[0176] Embodiment 65: The dosage form of any one of Embodiments 25 to 64, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 60 days.

[0177] Embodiment 66: The dosage form of any one of Embodiments 25 to 65, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 120 days.

[0178] Embodiment 67: A multi-component dosage form, comprising: choline; vitamin C; and a coating formulation, wherein the coating formulation comprises shellac, wherein the coating formulation coats the choline.

[0179] Embodiment 68: A multi-component dosage form, comprising: choline; vitamin C; and a coating formulation, wherein the coating formulation comprises shellac, wherein the vitamin C is coated with the coating formulation.

[0180] Embodiment 69: A multi-component dosage form comprising: choline, wherein the choline is coated with a first coating formulation comprising shellac; and vitamin C, wherein the vitamin C is coated with a second coating formulation comprising shellac.

[0181] Embodiment 70: A method for preventing spotting in a dosage form, the method comprising: providing an active ingredient comprising at least one of vitamin C and choline; coating the active ingredient in a coating formulation comprising shellac; and including the active ingredient coated in the coating formulation in a dosage form.

[0182] Embodiment 71: The method of embodiment 70, wherein the active ingredient is vitamin C.

[0183] Embodiment 72: The method of Embodiment 70 or Embodiment 71, wherein the active ingredient is choline.

[0184] Embodiment 73: The method of any one of Embodiments 70 to 72, wherein the active ingredients are choline and vitamin C.

[0185] Embodiment 74: The method of any one of embodiments 70 to 73, wherein the coating formulation further comprises a silicate.

[0186] Embodiment 75: The method of embodiment 74, wherein the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, or a combination thereof.

[0187] Embodiment 76: The method of embodiment 74 or embodiment 75, wherein the silicate is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0188] Embodiment 77: The method of embodiment 75, wherein the silica comprises colloidal silica or fumed silica.

[0189] Embodiment 78: The method according to any one of embodiments 70 to 77, wherein the coating formulation further comprises cellulose or a derivative thereof.

[0190] Embodiment 79: A method according to embodiment 78, wherein the cellulose or its derivative comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, or a combination thereof.

[0191] Embodiment 80: The method of embodiment 78 or embodiment 79, wherein the cellulose or a derivative thereof comprises hydroxypropyl cellulose.

[0192] Embodiment 81: The method of embodiment 80, wherein the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

[0193] Embodiment 82: The method of embodiment 78 or embodiment 79, wherein the cellulose or a derivative thereof comprises microcrystalline cellulose.

[0194] Embodiment 83: The method of embodiment 82, wherein the microcrystalline cellulose is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient and the second active ingredient.

[0195] Embodiment 84: The method of embodiment 78 or embodiment 79, wherein the cellulose or a derivative thereof comprises ethyl cellulose.

[0196] Embodiment 85: The method of embodiment 84, wherein the ethylcellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0197] Embodiment 86: The method of any one of embodiments 70 to 85, wherein the coating formulation further comprises starch.

[0198] Embodiment 87: The method of embodiment 86, wherein the starch comprises corn starch, potato starch, rice starch, wheat starch, tapioca starch, or a combination thereof.

[0199] Embodiment 88: The method of embodiment 86 or embodiment 87, wherein the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

[0200] Embodiment 89: The method of any one of Embodiments 70 to 88, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 18 days.

[0201] Embodiment 90: The method of any one of embodiments 70 to 89, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 60 days.

[0202] Embodiment 91: The method of any one of Embodiments 70 to 90, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 120 days.

[0203] Embodiment 92: The method of any one of Embodiments 70 to 91, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 18 days.

[0204] Embodiment 93: The method of any one of Embodiments 70 to 92, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 60 days.

[0205] Embodiment 94: The method of any one of Embodiments 70 to 93, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 120 days.

[0206] Embodiment 95: The method of any one of Embodiments 70 to 94, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 18 days.

[0207] Embodiment 96: The method of any one of Embodiments 70 to 95, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 60 days.

[0208] Embodiment 97: The method of any one of Embodiments 70 to 96, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 120 days.

[0209] Embodiment 98: The method of any one of Embodiments 70 to 97, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 18 days.

[0210] Embodiment 99: The method of any one of embodiments 70 to 98, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 60 days.

[0211] Embodiment 100: The method of any one of embodiments 70 to 99, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 120 days.

[0212] Example

[0213] Example 1: Exemplary Dosage Forms

[0214] The dosage form of the present disclosure comprising the following ingredients is prepared: vitamin A, vitamin D, biotin, magnesium stearate, vitamin K1, thiamine, riboflavin, niacin, vitamin B6, folic acid, vitamin B12, pantothenic acid, calcium, magnesium oxide, potassium chloride, iodine, phosphorus, ferrous fumarate, zinc oxide, copper oxide, manganese sulfate, molybdenum, chromium, picolinate, choline bitartrate and vitamin C. The preparation is used to test different coating preparations of the present disclosure. The preparation is modified to include choline in some cases. When the preparation does not include choline, hydroxypropyl cellulose is included in the preparation with the same amount (i.e. 280 mg). The amount of each component in the preparation is shown in Table 1.

[0215] Table 1

[0216]

[0217]

[0218] Figure 1 Tablets containing vitamin C but no choline are shown at different storage conditions after 18 days. The tablet composition is shown in Table 2. The storage conditions ranged from 10% relative humidity (RH) to 30% relative humidity and 25°C to 45°C. Spotting occurred to some extent under each storage condition, with the most pronounced spotting occurring at high temperature and high humidity. One tablet stored at 40°C and 75% RH showed severe spotting after only 24 hours.

[0219] Table 2

[0220]

[0221]

[0222] Figures 2A-2D Commercially available tablets stored for 18 days under different conditions are shown. Figure 2A , 2B and 2D tablets do not contain any choline, while Figure 2C The tablets in contained 30 mg choline. All tablets contained vitamin C. For the experiment, the tablets were cut in half. The tablets labeled "open" and "initial" were two halves of the same tablet, and the tablets labeled "capped" were halves of different tablets. The tablets labeled "open" were stored at 40°C and 75% RH for 24 hours. The tablets labeled "capped" were also stored at 40°C and 75% RH for 24 hours, but were covered with lids in a humidity chamber. The tablets labeled "initial" were stored at room temperature and 0% RH. Each tablet showed severe mottling under the "open" condition.

[0223] Figure 3 The spotting of tablets containing choline and vitamin C stored for 18 days under different temperature and humidity conditions is shown. The tablet composition is shown in Table 3. The temperature conditions tested were 25°C, 45°C, 65°C and 85°C, and the relative humidity conditions tested were 0%, 10%, 30% and 60%. As can be seen from the figure, the spotting accelerates with increasing temperature and humidity. At 60% relative humidity, the tablets were almost completely black after 18 days regardless of the temperature.

[0224] Table 3

[0225]

[0226]

[0227] Figure 4 The spotting of a tablet containing choline and vitamin C under refrigerated conditions is shown. The tablet had the tablet composition described in Table 3. The tablets were stored at 0% RH, 30% RH and 60% RH at 4°C for 18 days. After 18 days, the tablets stored at 60% RH still showed severe spotting even under refrigerated conditions.

[0228] Figure 5A and 5B The spotting of tablets containing vitamin C and various forms of choline compared to tablets without choline is shown. The general tablet composition is described in Table 4. The tablets were stored for 18 days at a temperature of 25°C or 45°C and a relative humidity of 10% or 30%. A tablet without choline was used as a reference. Figure 5A A reference tablet and tablets containing choline chloride and choline bitartrate are shown. Figure 5B Tablets containing choline chloride crystals blended with 1.5% calcium chloride, choline chloride crystals blended with 1.5% trimagnesium citrate, and choline chloride crystals blended with 2% magnesium stearate are shown. As used herein and in the remainder of Example 1, "choline chloride crystals blended with 1.5% calcium chloride" means that the choline chloride crystals are blended with 1.5% w / w calcium chloride relative to the combined mass of choline chloride and coating. In other words, every 98.5 mg of choline chloride in the tablet is blended with 1.5 mg of calcium chloride. From Figure 5A-5B It can be clearly seen in the graphs that spotting occurs under almost all storage conditions with the addition of various forms of choline. Furthermore, these graphs show that relative humidity in general has a strong influence on the extent of spotting.

[0229] Table 4

[0230] Element quantity unit Beta-carotene, vitamin A palmitate 2500 IU Vitamin D (Cholecalciferol) 400 IU Biotin (Vitamin H) 75 mcg Magnesium Stearate 12 mg Vitamin K1 (HPC) 20 mcg Thiamine B1 0.75 mg Riboflavin B2 0.85 mg Niacin B3 (Niacinamide) 10 mg Vitamin B6 1 mg Folic acid 0.2 mg Vitamin B12 3 mcg Calcium Pantothenate (Vitamin B5) 5 mg Calcium (dicalcium phosphate) 100 mg Magnesium Oxide 40 mg Potassium chloride 70 mg Potassium iodide 75 mcg Phosphorus (dicalcium phosphate) 100 mg Ferrous Fumarate 82 mg Zinc Oxide 3.75 mg Copper Oxide 0.4 mg Manganese sulfate 0.5 mg Molybdenum (sodium form) 18.75 mcg Chromium Picolinate 12 mcg choline 280 mg Vitamin C (ascorbic acid) 120 mg

[0231] Fig. 6A Spots of tablets containing various forms of vitamin C (VitC) and choline in the form of choline bitartrate are shown. The general composition of the tablets is provided in Table 5. Tablets without vitamin C were used as a reference. The tablets were stored for 18 days at a temperature of 25°C or 45°C and a relative humidity of 10%, 20% or 30%. Fig. 6AThe tablets tested in order from top to bottom contained: vitamin C in an alginate bead matrix; vitamin C in an ethylcellulose matrix; vitamin C in a vegetable mono- and diglyceride matrix (60% vitamin C); vitamin C in the form of calcium ascorbate; and a commercial vitamin C formulation containing ascorbic acid, soybean oil, and silicon dioxide. As expected from the previous tests, increasing temperature and relative humidity increased the degree of spotting for all the various vitamin C forms. Some degree of spotting occurred under all temperature and humidity conditions.

[0232] Table 5

[0233]

[0234]

[0235] Figure 6B The spotting of tablets containing vitamin C and choline and various coating formulations is shown. The tablet composition is described in Table 3. The tablets were stored at a temperature of 25°C or 45°C and a relative humidity of 20% or 30% for 18 days. Figure 6B The tablets tested in order from top to bottom contained: Vitamin C blended with 3.8% citrus bioflavonoids and 3.3% fatty acids; Vitamin C coated in a mixture of 0.13% oleic acid, 1.12% ethylcellulose, 0.02% medium chain triglycerides, 0.03% glycerol, and 1% calcium stearate (OEMGC); Vitamin C blended with 50% carnauba wax (CB); Vitamin C blended with 60% carnauba wax; and Vitamin C blended with ethylcellulose. Although the spotting was greatly reduced compared to the previous trials, these tablets still exhibited some degree of spotting.

[0236] Figure 7 Spotting of tablets containing both vitamin C and choline and various coating formulations is shown. The tablet compositions are described in Table 3. The tablets were stored for 18 days at a temperature of 25°C or 45°C and a relative humidity of 20% or 30%. Figure 7 The tablets tested in order from top to bottom included: tablets containing choline bitartrate coated with a mixture of shellac and talc; tablets containing vitamin C coated with a mixture of shellac and talc; tablets containing both vitamin C and choline bitartrate coated with a mixture of shellac and talc; and tablets containing choline bitartrate and vitamin C without coating. Figure 7 As can be clearly seen in the Figure 3, when vitamin C was coated with shellac alone, the mottling was reduced compared to the tablets containing choline bitartrate coated in shellac. However, tablets in which both vitamin C and choline bitartrate were coated with shellac showed little or no mottling.

[0237] Figure 8 The development of spotting of tablets containing both vitamin C and choline and a coating formulation containing a mixture of shellac and talc is shown. The tablet composition is described in Table 3. The tablets were stored at a temperature of 25°C or 45°C and a relative humidity of 30% for 18 days. Spotting of any tablet was not observed. However, due to regulatory regulations, talc cannot be used in certain pharmaceutical applications. Therefore, more talc-free coating formulations are developed for pharmaceutical applications.

[0238] Fig. 9 The progression of spotting of tablets containing vitamin C or choline bitartrate with a shellac coating thereon is shown. The tablet compositions are described in Table 3. The percentages refer to the weight percentage of the active ingredient relative to the combined weight of the active ingredient and the coating; i.e. a tablet labeled "Shellac-VitC (87%)" means that the tablet contains 87% by weight of vitamin C and 13% by weight of coating. The shellac coating does not contain any other additives, such as talc; i.e. the coating contains only shellac. The tablets were stored for 18 days at a temperature of 25°C or 45°C and a relative humidity of 20% or 30%. The images show tablets on days 0, 4, 7, 11, 14, and 18. Tablets containing 87% vitamin C coated with shellac showed spotting only at high temperatures and high humidity. However, the remaining tablets ranged from almost no spotting to no spotting.

[0239] Fig.10 The progression of spotting of tablets containing vitamin C or choline bitartrate with a shellac coating thereon is shown. The tablet compositions are described in Table 3. The tablets were stored for 18 days at a temperature of 25°C or 45°C and a relative humidity of 20% or 30%. The images show tablets on days 0, 4, 7, 11, 14, and 18. Tablets without vitamin C and uncoated ascorbic acid are provided for reference. Tablets containing shellac-coated vitamin C and choline bitartrate progressed from almost no spotting to no spotting.

[0240] Fig.11 The progression of mottling of tablets containing either vitamin C or choline bitartrate or both with shellac coating thereon is shown. The tablet compositions are described in Table 3. The tablets were stored for 18 days at a temperature of 45°C and a relative humidity of 20% or 30%. The images show tablets on days 0, 4, 7, 11, 14 and 18. It can be clearly seen that the tablets containing shellac coated choline bitartrate and vitamin C showed no mottling. In addition, the tablets containing shellac coated choline bitartrate or shellac coated vitamin C still showed little or no mottling.

[0241] Coating formulations were prepared to coat choline bitartrate and ascorbic acid (vitamin C) within the dosage form. Table 6 shows the different formulations prepared.

[0242] Table 6

[0243]

[0244] Example 2: Colorimeter Measurement

[0245] A HunterLab UltraScan VIS colorimeter was used to perform colorimetric analysis on the tablets. One or more tablets were retained from each tablet tested as an initial colorimeter measurement. The retained tablets were stored in a dark desiccator to prevent spotting.

[0246] Grind the tablets into a powder using a mortar and pestle. Then transfer the powder to a 100 mL capacity amber flask. Add 80-90 mL of distilled water to the flask. Cover the flask with a lid and shake the contents several times. Then, fill the flask to the 100 mL mark with distilled water and shake again.

[0247] Next, transfer 25mL of the liquid from the flask to a 50mL centrifuge tube. Spin the tube at 3200rpm for 10 minutes. Decant the liquid and pour it into a clean colorimeter cuvette. Place the cuvette in the colorimeter and measure the color spectrum of the liquid. Measure the reserve tablet first and save it as a reference or origin. Calculate the total color difference (ΔE). ΔE less than one is usually an imperceptible color change and is therefore the most desired.

[0248] Figures 12A-12G Colorimeter measurements of tablets containing coating formulations of the present disclosure are shown. All tablets were stored at 30% RH for 18 days. Fig. 12A Colorimeter measurements of tablets containing coating formulations 1 and 4 described in Table 6 are shown. Fig. 12B Colorimeter measurements of tablets containing coating formulations 1 and 5 described in Table 6 are shown. Fig. 12C Colorimeter measurements of tablets containing coating formulations 2 and 4 described in Table 6 are shown. Fig.12D Colorimeter measurements of tablets containing coating formulations 2 and 5 described in Table 6 are shown. Fig.12E Colorimeter measurements of tablets containing coating formulations 3 and 4 described in Table 6 are shown. Fig.12F Colorimeter measurements of tablets containing coating formulations 3 and 5 described in Table 6 are shown. Figure 12G Shown are colorimeter measurements of tablets containing coating formulations 1 and 5 plus talc as described in Table 6. Colorimeter measurements were taken at various times over the course of 18 days.

[0249] Fig.13 Shows Figures 12A-12GThe ΔE measured for each tablet on days 0, 4, 7, 11, 14, and 18, and the average ΔE measured for each tablet were included. Overall, the average ΔE ranged from 0.85 to 2.03, indicating a low degree of color variation between tablets.

[0250] Figures 14A-14B Colorimeter measurements of tablets without the coating formulation of the present disclosure are shown. Fig.14A Shown is a colorimeter measurement of a tablet containing vitamin C and no choline. Fig. 14B Colorimeter measurements of tablets containing vitamin C and choline chloride are shown. Clearly, Figures 14A-14B Tablets measured in Figures 12A-12G The tablets shown show a greater color change than the reference tablets. Typically, tablets without the coating formulations of the present disclosure have an average ΔE of about 7-10. In a tablet containing choline chloride coated with calcium chloride, the ΔE at day 18 was 68.7, showing a greater color change than the reference tablets.

[0251] Fig. 14C Shown 18 days later for Figures 14A-14B The cuvette on the left is a sample of a tablet containing vitamin C but no choline. The cuvette on the right is a sample of a tablet containing vitamin C and choline chloride.

Claims

1. A coating formulation comprising shellac, wherein the coating formulation coats at least one active ingredient in a multi-ingredient dosage form.

2. The coating formulation according to claim 1, wherein the concentration of the at least one active ingredient is about 50.0% by mass to about 95.0% by mass relative to the total mass of the at least one active ingredient and the coating formulation.

3. The coating formulation of claim 1 or claim 2, wherein the at least one active ingredient comprises vitamin C.

4. The coating formulation according to claim 3, wherein the vitamin C is selected from the group consisting of ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, and any combination thereof.

5. The coating formulation according to claim 3 or claim 4, wherein the vitamin C is present in an amount of about 50% to about 95% by mass relative to the combined mass of the vitamin C and the coating formulation.

6. The coating formulation according to any one of claims 1 to 5, wherein the at least one active ingredient comprises choline.

7. The coating formulation according to claim 6, wherein the choline is selected from the group consisting of choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, alpha glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, esters of choline and DHA, esters of choline and 3-methyl-2-hexenoic acid (MHA), esters of choline and medium chain triglycerides, other esters of choline and fatty acids, other salts of choline, or combinations thereof.

8. The coating formulation according to claim 6 or claim 7, wherein the choline is present in an amount of about 50% to about 95% by mass relative to the combined mass of the choline and the coating formulation.

9. The coating formulation according to any one of claims 1 to 8, wherein the shellac is present in an amount of about 1 mass % to about 50 mass % relative to the combined mass of the at least one active ingredient and the coating formulation.

10. The coating formulation according to any one of claims 1 to 9, wherein the coating formulation further comprises a silicate.

11. The coating formulation of claim 10, wherein the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, or a combination thereof.

12. The coating formulation according to claim 10 or claim 11, wherein the silicate is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

13. The coating formulation according to claim 11, wherein the silicon dioxide comprises colloidal silicon dioxide or fumed silicon dioxide.

14. The coating formulation according to any one of claims 1 to 13, wherein the coating formulation further comprises cellulose or a derivative thereof.

15. The coating formulation of claim 14, wherein the cellulose or its derivative comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hypromellose, carboxymethyl cellulose, or a combination thereof.

16. The coating formulation according to claim 14 or claim 15, wherein the cellulose or a derivative thereof comprises hydroxypropyl cellulose.

17. The coating formulation according to claim 16, wherein the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0% by mass to about 10% by mass relative to the combined mass of the coating formulation and the at least one active ingredient.

18. A coating formulation according to claim 14 or claim 15, wherein the cellulose or derivative thereof comprises microcrystalline cellulose.

19. The coating formulation according to claim 18, wherein the microcrystalline cellulose is present in the coating formulation in an amount of about 0% to about 25% by mass relative to the combined mass of the coating formulation and the first active ingredient and the second active ingredient.

20. The coating formulation of claim 14 or claim 15, wherein the cellulose or a derivative thereof comprises ethyl cellulose. 21 . The coating preparation according to claim 20 , wherein the ethylcellulose is present in the coating preparation in an amount of about 0% by mass to about 10% by mass relative to the combined mass of the coating preparation and the first active ingredient or the second active ingredient.

22. The coating formulation according to any one of claims 1 to 21, wherein the coating formulation further comprises starch.

23. The coating formulation of claim 22, wherein the starch comprises corn starch, potato starch, rice starch, wheat starch, tapioca starch, or a combination thereof.

24. The coating formulation according to claim 22 or claim 23, wherein the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

25. A multi-component dosage form, comprising: at least one active ingredient; as well as A coating formulation comprising shellac, wherein the coating formulation coats the at least one active ingredient.

26. The dosage form of claim 25, wherein the at least one active ingredient comprises vitamin C.

27. The dosage form of claim 26, wherein the vitamin C is present in the dosage form in an amount of about 1 mg to about 2000 mg.

28. The dosage form of claim 26 or claim 27, wherein the vitamin C is selected from the group consisting of ascorbic acid, ferrous ascorbate, magnesium ascorbate, sodium ascorbate, calcium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate, lithium ascorbate, potassium ascorbate, nickel ascorbate, silver ascorbate, and any combination thereof.

29. The dosage form according to any one of claims 25 to 28, wherein the at least one active ingredient comprises choline.

30. The dosage form of claim 29, wherein the choline is present in the dosage form in an amount of about 1 mg to about 2000 mg.

31. The dosage form of claim 29 or claim 30, wherein the choline is selected from the group consisting of choline chloride, choline bitartrate, phosphatidylcholine, choline dihydrogen citrate, alpha glycerophosphorylcholine, cytidine diphosphate choline, choline folic acid, esters of choline and DHA, esters of choline and 3-methyl-2-hexenoic acid (MHA), esters of choline and medium chain triglycerides, other esters of choline and fatty acids, other salts of choline, or combinations thereof.

32. The dosage form according to any one of claims 25 to 31, wherein the shellac is present in an amount of about 1% to about 50% by mass relative to the total mass of the at least one active ingredient and the coating formulation.

33. The dosage form according to any one of claims 25 to 32, wherein the at least one active ingredient is present in an amount of about 50.0 mass % to about 95.0 mass % relative to the combined mass of the at least one active ingredient and the coating formulation.

34. The dosage form according to any one of claims 25 to 33, wherein the at least one active ingredient comprises vitamin C and choline, and wherein the choline is not coated by the coating formulation.

35. The dosage form according to any one of claims 25 to 33, wherein the at least one active ingredient comprises choline, and the dosage form further comprises vitamin C, wherein the vitamin C is not coated by the coating formulation.

36. The dosage form according to any one of claims 25 to 33, wherein the at least one active ingredient comprises vitamin C, and the dosage form further comprises choline, wherein the choline is not coated by the coating formulation.

37. The dosage form according to any one of claims 25 to 36, wherein the dosage form is a tablet, capsule, gummies, beverages, sticks, suspensions, granulations, powders, lozenges, pastilles, granules, pills, caplets.

38. The dosage form of any one of claims 25 to 37, wherein the dosage form further comprises at least one of vitamins, minerals, supplements, and excipients.

39. The dosage form according to any one of claims 25 to 38, wherein the dosage form further comprises an additional active ingredient that is not coated by the coating formulation.

40. The dosage form of any one of claims 25 to 39, wherein the coating formulation further comprises a silicate.

41. The dosage form of claim 40, wherein the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, or a combination thereof.

42. The dosage form of claim 40 or claim 41, wherein the silicate is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

43. The dosage form of claim 41, wherein the silicon dioxide comprises colloidal silicon dioxide or fumed silicon dioxide.

44. The dosage form according to any one of claims 25 to 43, wherein the coating formulation further comprises cellulose or a derivative thereof.

45. The dosage form of claim 44, wherein the cellulose or derivative thereof comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hypromellose, carboxymethyl cellulose, or a combination thereof.

46. ​​The dosage form of claim 44 or claim 45, wherein the cellulose or derivative thereof comprises hydroxypropyl cellulose.

47. The dosage form of claim 46, wherein the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

48. The dosage form of claim 44 or claim 45, wherein the cellulose or derivative thereof comprises microcrystalline cellulose.

49. The dosage form of claim 48, wherein the microcrystalline cellulose is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient and the second active ingredient.

50. The dosage form of claim 44 or claim 45, wherein the cellulose or derivative thereof comprises ethyl cellulose.

51. The dosage form of claim 50, wherein the ethylcellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

52. The dosage form of any one of claims 25 to 51, wherein the coating formulation further comprises starch.

53. The dosage form of claim 52, wherein the starch comprises corn starch, potato starch, rice starch, wheat starch, tapioca starch, or a combination thereof.

54. The dosage form of claim 52 or claim 53, wherein the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

55. The dosage form according to any one of claims 25 to 54, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 18 days.

56. The dosage form according to any one of claims 25 to 55, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 60 days.

57. The dosage form according to any one of claims 25 to 56, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 120 days.

58. The dosage form according to any one of claims 25 to 57, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 18 days.

59. The dosage form according to any one of claims 25 to 58, wherein the multi-component dosage form is substantially free of spotting after storage at 45°C and 20% relative humidity for about 60 days.

60. The dosage form according to any one of claims 25 to 59, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 120 days.

61. The dosage form of any one of claims 25 to 60, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 18 days.

62. The dosage form according to any one of claims 25 to 61, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 60 days.

63. The dosage form according to any one of claims 25 to 62, wherein the multi-component dosage form is substantially free of spotting after storage at 25°C and 30% relative humidity for about 120 days.

64. The dosage form according to any one of claims 25 to 63, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 18 days.

65. The dosage form according to any one of claims 25 to 64, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 60 days.

66. The dosage form according to any one of claims 25 to 65, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 120 days.

67. A multi-component dosage form, comprising: choline; Vitamin C; as well as A coating formulation comprising shellac, The coating preparation coats the choline.

68. A multi-component dosage form, comprising: choline; Vitamin C; as well as A coating formulation comprising shellac, The coating preparation is used to coat the vitamin C.

69. A multi-component dosage form, comprising: Choline, wherein the choline is coated with a first coating formulation comprising shellac; as well as Vitamin C, wherein the vitamin C is coated with a second coating formulation comprising shellac.

70. A method for preventing spotting in a dosage form, the method comprising: providing an active ingredient comprising at least one of vitamin C and choline; coating the active ingredient in a coating formulation comprising shellac; as well as The active ingredient coated in the coating formulation is contained in a dosage form.

71. The method of claim 70, wherein the active ingredient is vitamin C.

72. The method of claim 70 or claim 71 , wherein the active ingredient is choline.

73. The method of any one of claims 70 to 72, wherein the active ingredients are choline and vitamin C.

74. The method of any one of claims 70 to 73, wherein the coating formulation further comprises a silicate.

75. The method of claim 74, wherein the silicate comprises silicon dioxide, bentonite, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, silicified microcrystalline cellulose, or a combination thereof.

76. The method of claim 74 or claim 75, wherein the silicate is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

77. The method of claim 75, wherein the silica comprises colloidal silica or fumed silica.

78. The method of any one of claims 70 to 77, wherein the coating formulation further comprises cellulose or a derivative thereof.

79. The method of claim 78, wherein the cellulose or derivative thereof comprises microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hypromellose, carboxymethyl cellulose, or a combination thereof.

80. The method of claim 78 or claim 79, wherein the cellulose or derivative thereof comprises hydroxypropyl cellulose.

81. The method of claim 80, wherein the hydroxypropyl cellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the at least one active ingredient.

82. The method of claim 78 or claim 79, wherein the cellulose or derivative thereof comprises microcrystalline cellulose.

83. The method of claim 82, wherein the microcrystalline cellulose is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient and the second active ingredient.

84. The method of claim 78 or claim 79, wherein the cellulose or derivative thereof comprises ethyl cellulose.

85. The method of claim 84, wherein the ethylcellulose is present in the coating formulation in an amount of about 0 mass % to about 10 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

86. The method of any one of claims 70 to 85, wherein the coating formulation further comprises starch.

87. The method of claim 86, wherein the starch comprises corn starch, potato starch, rice starch, wheat starch, tapioca starch, or a combination thereof.

88. The method of claim 86 or claim 87, wherein the starch is present in the coating formulation in an amount of about 0 mass % to about 25 mass % relative to the combined mass of the coating formulation and the first active ingredient or the second active ingredient.

89. The method of any one of claims 70 to 88, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 18 days.

90. The method of any one of claims 70 to 89, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 60 days.

91. The method of any one of claims 70 to 90, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 20% relative humidity for about 120 days.

92. The method of any one of claims 70 to 91, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 18 days.

93. The method of any one of claims 70 to 92, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 60 days.

94. The method of any one of claims 70 to 93, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 20% relative humidity for about 120 days.

95. The method of any one of claims 70 to 94, wherein the multi-component dosage form exhibits little spotting after storage for about 18 days at 25°C and 30% relative humidity.

96. The method of any one of claims 70 to 95, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 60 days.

97. The method of any one of claims 70 to 96, wherein the multi-component dosage form exhibits little spotting after storage at 25°C and 30% relative humidity for about 120 days.

98. The method of any one of claims 70 to 97, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 18 days.

99. The method of any one of claims 70 to 98, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 60 days.

100. The method of any one of claims 70 to 99, wherein the multi-component dosage form exhibits little spotting after storage at 45°C and 30% relative humidity for about 120 days.